secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0000950170-24-009397
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma grants options to 7 non-employee directors; stockholders re-elect two directors at annual meeting
--------------------------------------------------------------------------------

- Board granted options to purchase 6,000 shares each to 7 non-employee directors at $1.64 per share, vesting monthly over 12 months.
- Stockholders re-elected Michael Bristow (6,952,545 for) and Robert Conway (6,758,409 for) as directors for three-year terms.
- Ratified KPMG LLP as independent auditor for FY2023 with 10,286,650 for, 263,929 against, 68,141 abstain.
- Advisory say-on-pay resolution approved: 6,548,473 for, 1,472,454 against, 19,941 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/abio-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-009397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer